MedImmune licenses Pfizer’s tremelimumab
Pfizer Inc. has granted AstraZeneca PLC’s biologics division MedImmune LLC global rights to develop its oncology compound tremelimumab (CP675206). Pfizer retains rights for use with specific types of combination therapies.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com